SAR191801 | CAS#1234708-04-3 | hPGDS inhibitor

MedKoo Cat#: 527879 | Name: SAR191801

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SAR191801, also known as hPGDS-IN-1, is a novel hPGDS inhibitor.

Chemical Structure

SAR191801

CAS#1234708-04-3

Theoretical Analysis

MedKoo Cat#: 527879

Name: SAR191801

CAS#: 1234708-04-3

Chemical Formula: C22H20N6O3

Exact Mass: 416.1597

Molecular Weight: 416.44

Elemental Analysis: C, 63.45; H, 4.84; N, 20.18; O, 11.53

Price and Availability

Size	Price	Availability
1mg	USD 450.00	2 weeks
5mg	USD 750.00	2 Weeks
10mg	USD 1,100.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SAR 191801; SAR-191801; SAR191801; hPGDS-IN-1; hPGDS IN 1

IUPAC/Chemical Name

N-[[3-[5-(1-Hydroxy-1-methylethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-2-(2-pyridinyl)-5-pyrimidinecarboxamide

InChi Key

VJCLAPUACUQZOV-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H20N6O3/c1-22(2,30)21-27-18(28-31-21)15-7-5-6-14(10-15)11-26-20(29)16-12-24-19(25-13-16)17-8-3-4-9-23-17/h3-10,12-13,30H,11H2,1-2H3,(H,26,29)

SMILES Code

O=C(C1=CN=C(C2=NC=CC=C2)N=C1)NCC3=CC=CC(C4=NOC(C(C)(O)C)=N4)=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Biological target:

SAR191801 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay.

In vitro activity:

To be determined

In vivo activity:

To be determined

Preparing Stock Solutions

The following data is based on the product molecular weight 416.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

To be determined

In vitro protocol:

To be determined

In vivo protocol:

To be determined

[1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414. https://patents.google.com/patent/WO2011044307A1/en [2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715. https://patents.google.com/patent/WO2010080563A2/en [3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 19 https://pubs.acs.org/doi/10.1021/op300210j